➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Medtronic
Dow
McKinsey
Mallinckrodt

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Napabucasin


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Napabucasin?

Napabucasin is an investigational drug.

There have been 20 clinical trials for Napabucasin. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Boston Biomedical, Inc, 1Globe Biomedical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.

There are twenty-eight US patents protecting this investigational drug and two hundred and nineteen international patents.

Recent Clinical Trials for Napabucasin
TitleSponsorPhase
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored ProtocolsBoston Biomedical, IncPhase 1
A Study of Napabucasin(GB201) in Combination With Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer1Globe Biomedical Co., Ltd.Phase 3
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerAustralasian Gastro-Intestinal Trials GroupPhase 2

See all Napabucasin clinical trials

Clinical Trial Summary for Napabucasin

Top disease conditions for Napabucasin
Top clinical trial sponsors for Napabucasin

See all Napabucasin clinical trials

US Patents for Napabucasin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Napabucasin   Get Started Free Anticancer agent Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)   Get Started Free
Napabucasin   Get Started Free 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof Boston Biomedical, Inc. (Cambridge, MA)   Get Started Free
Napabucasin   Get Started Free Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer BOSTON BIOMEDICAL, INC. (Cambridge, MA) SUMITOMO DAINIPPON PHARMA CO., LTD. (Osaka-shi, Osaka, JP)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
AstraZeneca
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.